Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study

Autor:	Darren M. Brenner, Susan M. Fox, Patricia D'Astoli, Charles Argoff, David S. Reasner, Wieslaw Bochenek, Christopher R. O'Dea, Brooks D. Cash, Rick Blakesley
Rok vydání:	2020
Předmět:	medicine.medical_specialty Constipation Placebo Gastroenterology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial Double-Blind Method 030202 anesthesiology law Internal medicine medicine Clinical endpoint Humans Adverse effect Linaclotide Bowel movement Opioid constipation business.industry digestive oral and skin physiology Guanylate cyclase-C agonist Analgesics Opioid Opioid use Anesthesiology and Pain Medicine Treatment Outcome Neurology chemistry Opioid Defecation Neurology (clinical) medicine.symptom Chronic Pain business Peptides Opioid-Induced Constipation 030217 neurology & neurosurgery medicine.drug Research Paper
Zdroj:	Pain
ISSN:	1872-6623
Popis:	Supplemental Digital Content is Available in the Text. In patients with chronic noncancer pain and opioid-induced constipation, linaclotide significantly improved stool consistency, straining, abdominal bloating, and treatment satisfaction vs placebo and was well tolerated. Constipation is the most common adverse event (AE) of opioid therapy. This multicenter, phase 2 study evaluated the efficacy and safety of linaclotide in treating opioid-induced constipation (OIC) in patients with chronic noncancer pain syndromes (NCT02270983). Adults with OIC (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d034ec8417096fe1ab077ce777b1d6 https://pubmed.ncbi.nlm.nih.gov/32310620 Zobrazit plný text záznamu